About sotaterce pt
Activin signaling inhibitor
Used for
- Treats pulmonary arterial hypertension in adults to improve exercise ability and reduce risk of worsening.
Usual adult dose
Usually 0.3 mg/kg under the skin initially, then 0.7 mg/kg every 3 weeks.
Common side effects
- Low red blood cell count
- Low platelet count
- Nosebleeds
- Headache
Important warnings
- Blood tests are needed before and during treatment to monitor blood counts.
- May cause serious bleeding, especially with low platelets or blood-thinning medicines.
- Can harm an unborn baby; pregnancy testing and effective contraception are required during treatment and for 4 months afterward.
- Do not start if blood pressure is uncontrolled.
Pregnancy
May cause fetal harm. Avoid pregnancy during treatment and for 4 months after the last dose.
Breastfeeding
It is unknown whether sotatercept passes into breast milk; breastfeeding is not recommended during treatment and for 4 months afterward.
Interactions
- Blood thinners and antiplatelet medicines may increase bleeding risk.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.